# Synchronous Occurrence of Acute Myeloid Leukemia and Multiple Myeloma: A Case Report and Literature Review

**Authors:** Tajudeen Musbau, Bahaa Al-Bubseeree

PMC · DOI: 10.7759/cureus.83730 · Cureus · 2025-05-08

## TL;DR

A 60-year-old man was diagnosed with both acute myeloid leukemia and multiple myeloma, a rare condition that was resistant to treatment.

## Contribution

This case report highlights the rare synchronous occurrence and treatment challenges of AML and MM in a single patient.

## Key findings

- The patient had AML with myelodysplastic molecular changes and 11% plasma cells in the bone marrow post-treatment.
- The patient showed poor response to induction and intermediate chemotherapy, with residual blasts persisting.
- The myeloma component was not treated due to the patient's poor fitness for intensive therapies.

## Abstract

Multiple myeloma (MM) and acute myeloid leukemia (AML) are malignant clonal disorders with divergent lineages. It is extremely uncommon for both conditions to be diagnosed simultaneously in a patient. This case report examines the uncommon occurrence of AML alongside MM in a 60-year-old male patient. The diagnosis of AML was based on the World Health Organization benchmark, and the patient was categorized as having AML with myelodysplastic defining molecular changes. The patient completed the first cycle of induction chemotherapy with daunorubicin, cytarabine, and gemtuzumab ozogamicin but had a poor response, indicating refractory disease. A bone marrow aspiration following treatment revealed 30% blasts and 11% plasma cells. These plasma cells were CD138 positive and were not present at the time of diagnosis. Additionally, M-protein was detected in the blood. Intermediate chemotherapy with venetoclax and azacitidine was considered, as the patient was not fit for the combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin. Furthermore, the myeloma was not treated as he was not fit for any intensive chemotherapy. The patient’s disease was refractory despite four cycles of venetoclax and azacitidine, as evident by residual blasts of 32% in the bone marrow.

## Linked entities

- **Chemicals:** daunorubicin (PubChem CID 30323), cytarabine (PubChem CID 6253), venetoclax (PubChem CID 49846579), azacitidine (PubChem CID 9444), fludarabine (PubChem CID 657237), idarubicin (PubChem CID 42890)
- **Diseases:** acute myeloid leukemia (MONDO:0015667), multiple myeloma (MONDO:0009693), myelodysplastic syndrome (MONDO:0018881)

## Full-text entities

- **Genes:** MYOM2 (myomesin 2) [NCBI Gene 9172] {aka TTNAP}, SDC1 (syndecan 1) [NCBI Gene 6382] {aka CD138, SDC, SYND1, syndecan}
- **Diseases:** myelodysplastic (MESH:D009190), AML (MESH:D015470), MM (MESH:D009101)
- **Chemicals:** venetoclax (MESH:C579720), cytarabine (MESH:D003561), daunorubicin (MESH:D003630), azacitidine (MESH:D001374), gemtuzumab ozogamicin (MESH:D000079982), idarubicin (MESH:D015255), fludarabine (MESH:C024352)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12145069/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12145069/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12145069/full.md

---
Source: https://tomesphere.com/paper/PMC12145069